A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update.

被引：0
|
作者：
van Oosterom, A
Reichardt, P
Blay, JY
Dumez, H
Fletcher, J
Debiec-Rychter, M
Shand, N
Drimitrijevic, S
Yap, A
Demetri, G
机构：
[1] UZ Gasthuisberg, Louvain, Belgium
[2] Charite, Berlin, Germany
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Novartis Pharm AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：824S / 824S
页数：1
相关论文
共 50 条
  • [41] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).
    Reichardt, P.
    Casali, P. G.
    Blay, J.
    Von Mehren, M.
    Schoffski, P.
    Hosseinzadeh, S.
    Tanaka, C.
    Gsponer, T.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 531S - 531S
  • [43] A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors.
    Tabernero, J
    Rojo, F
    Burris, H
    Casado, E
    Macarulla, T
    Jones, S
    Dimitrijevic, S
    Hazell, K
    Shand, N
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 193S - 193S
  • [44] Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    Shirao, Kuniaki
    Nishida, Toshirou
    Doi, Toshihiko
    Komatsu, Yoshito
    Muro, Kei
    Li, Yinhua
    Ueda, Eiji
    Ohtsu, Atsushi
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (06) : 866 - 875
  • [45] Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    Kuniaki Shirao
    Toshirou Nishida
    Toshihiko Doi
    Yoshito Komatsu
    Kei Muro
    Yinhua Li
    Eiji Ueda
    Atsushi Ohtsu
    Investigational New Drugs, 2010, 28 : 866 - 875
  • [46] Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.
    Wang, D.
    Zhang, Q.
    Blanke, C. D.
    Demetri, G. D.
    Heinrich, M. C.
    Watson, J. C.
    Hoffman, J. P.
    Okuno, S. H.
    Kane, J. M.
    vonMehren, M.
    Eisenberg, B. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) treatment in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
    Cho, H.
    Ryu, M-H.
    Chae, H.
    Lee, S. M.
    Park, Y.
    Kim, K-H.
    Kim, C. W.
    Kim, B. S.
    Yoo, M-W.
    Ma, J.
    Beck, M. Y.
    Kim, M.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Hernandez, I
    Rackoff, W
    Faderl, S
    Thomas, D
    Ferrajoli, A
    Talpaz, M
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 289A - 289A
  • [49] Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST).
    Dileo, P
    Rankin, CJ
    Benjamin, RS
    von Mehren, M
    Blanke, C
    Bramwell, V
    Maki, R
    Fletcher, C
    Borden, EC
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 824S - 824S
  • [50] CLINICAL BENEFIT WITH REGORAFENIB ACROSS SUBGROUPS AND POST-PROGRESSION IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) AFTER PROGRESSION ON IMATINIB (IM) AND SUNITINIB (SU): PHASE 3 GRID TRIAL UPDATE
    Casali, P. G.
    Reichardt, P.
    Kang, Y.
    Blay, J.
    Rutkowski, P.
    Gelderblom, H.
    Hohenberger, P.
    Leahy, M.
    von Mehren, M.
    Joensuu, H.
    Badalamenti, G.
    Blackstein, M.
    Le Cesne, A.
    Schoffski, P.
    Maki, R.
    Xu, J.
    Nishida, T.
    Kuss, I.
    Laurent, D.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 478 - 479
12345